Offerings - Offering: 1 |
Sep. 01, 2026
USD ($)
shares
|
|---|---|
| Offering: | |
| Fee Previously Paid | false |
| Other Rule | true |
| Security Type | Equity |
| Security Class Title | Common Stock, par value $0.001 per share |
| Amount Registered | shares | 1,569,100,441 |
| Maximum Aggregate Offering Price | $ 5,225.10 |
| Fee Rate | 0.01381% |
| Amount of Registration Fee | $ 0.72 |
| Rule 457(f) | true |
| Amount of Securities Received | shares | 1,569,100,441 |
| Value of Securities Received, Per Share | 0.00000333 |
| Value of Securities Received | $ 5,225.10 |
| Fee Note MAOP | $ 5,225.10 |
| Offering Note | 1. Represents the maximum number of shares of Common Stock, par value $0.001 per share ("Fulcrum Common Stock"), of Fulcrum Therapeutics, Inc. ("Fulcrum"), that are expected to be issued (or become issuable) to equityholders of Slate Medicines, Inc.("Slate") in the proposed merger of Fusion Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Fulcrum, with and into Slate, with Slate surviving the merger, and as part of the same overall transaction, Slate will merge with and into Fusion Merger Sub II, LLC, a Delaware limited liability company and a wholly owned subsidiary of Fulcrum, with Fusion Merger Sub II, LLC continuing as a wholly owned subsidiary of Fulcrum and the surviving entity of the merger. The amount of Fulcrum common stock to be registered includes the estimated maximum number of shares of Fulcrum common stock that are expected to be issued (or become issuable) pursuant to the merger, without taking into account the effect of a reverse stock split of Fulcrum's common stock, assuming an estimated pre-split exchange ratio (which is subject to adjustment prior to the closing of the merger) of approximately 24.8186 shares of Fulcrum common stock for each outstanding share of common stock of Slate. 2. Estimated solely for the purpose of calculating the registration fee under Rule 457(f)(2) under the Securities Act of 1933, as amended. Slate is a private company, no market exists for its securities, and Slate has an accumulated capital deficit. Therefore, the proposed maximum aggregate offering price is calculated based on an aggregate offering amount equal to one-third of the aggregate par value of the Slate Common Stock that will be exchanged in the Merger. 3. In accordance with Rule 416 under the Securities Act of 1933, as amended, this registration statement shall be deemed to cover any securities that may from time to time be offered or issued resulting from forward or reverse stock splits, stock dividends or similar transactions. |